{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:45:45Z","timestamp":1790703945837,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10741-022-10239-5","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T20:04:28Z","timestamp":1650312268000},"page":"1991-2003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4016","authenticated-orcid":false,"given":"Filippos","family":"Triposkiadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Skoularigis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"issue":"4","key":"10239_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1515\/hsz-2019-0386","volume":"401","author":"F Hofmann","year":"2020","unstructured":"Hofmann F (2020) The cGMP system: components and function. Biol Chem 401(4):447\u2013469","journal-title":"Biol Chem"},{"issue":"6","key":"10239_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S2213-2600(20)30567-1","volume":"9","author":"RP Frantz","year":"2021","unstructured":"Frantz RP (2021) Replace and the role of riociguat in pulmonary arterial hypertension therapy. Lancet Respir Med 9(6):546\u2013547","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10239_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A, Duggan S (2021) Vericiguat: first approval. Drugs 81(6):721\u2013726","journal-title":"Drugs"},{"key":"10239_CR4","doi-asserted-by":"crossref","unstructured":"Xanthopoulos A, Tryposkiadis K, Triposkiadis F, Fukamachi K, Soltesz EG, Young JB, Wolski K, Blackstone EH, Starling RC (2020) Postimplant phosphodiesterase type 5 inhibitors use is associated with lower rates of thrombotic events after left ventricular assist device implantation. J Am Heart Assoc\u00a09(14):e015897","DOI":"10.1161\/JAHA.119.015897"},{"issue":"2","key":"10239_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jchf.2021.09.008","volume":"10","author":"A Xanthopoulos","year":"2022","unstructured":"Xanthopoulos A, Wolski K, Wang Q, Blackstone EH, Randhawa VK, Soltesz EG, Young JB, Nissen SE, Estep JD, Triposkiadis F et al (2022) Postimplant phosphodiesterase-5 inhibitor use in centrifugal flow left ventricular assist devices. JACC Heart Fail 10(2):89\u2013100","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10239_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","volume":"115","author":"YC Lai","year":"2014","unstructured":"Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT (2014) Pulmonary arterial hypertension: the clinical syndrome. Circ Res 115(1):115\u2013130","journal-title":"Circ Res"},{"issue":"15","key":"10239_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/eurheartj\/ehx751","volume":"39","author":"N Galie","year":"2018","unstructured":"Galie N, Manes A, Dardi F, Palazzini M (2018) Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease. Eur Heart J 39(15):1265\u20131268","journal-title":"Eur Heart J"},{"key":"10239_CR8","doi-asserted-by":"crossref","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53(1)","DOI":"10.1183\/13993003.01913-2018"},{"issue":"4","key":"10239_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M et al (2015) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS): Endorsed by: association for european paediatric and congenital cardiology (AEPC), International society for heart and lung transplantation (ISHLT). Eur Respir J 46(4):903\u2013975","journal-title":"Eur Respir J"},{"issue":"2","key":"10239_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.14797\/RKQN5397","volume":"17","author":"F Macera","year":"2021","unstructured":"Macera F, Vachiery JL (2021) Management of pulmonary hypertension in left heart disease. Methodist Debakey Cardiovasc J 17(2):115\u2013123","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"10239_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccl.2021.08.007","volume":"40","author":"AK Alamri","year":"2022","unstructured":"Alamri AK, Ma CL, Ryan JJ (2022) Left heart disease-related pulmonary hypertension. Cardiol Clin 40(1):69\u201376","journal-title":"Cardiol Clin"},{"issue":"17","key":"10239_CR12","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.117.031608","volume":"137","author":"AU Fayyaz","year":"2018","unstructured":"Fayyaz AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA, Frantz RP, Jenkins SM, Redfield MM (2018) Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 137(17):1796\u20131810","journal-title":"Circulation"},{"issue":"4","key":"10239_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cjca.2020.11.003","volume":"37","author":"F Lee","year":"2021","unstructured":"Lee F, Mielniczuk LM (2021) Pulmonary hypertension due to left heart disease-a practical approach to diagnosis and management. Can J Cardiol 37(4):572\u2013584","journal-title":"Can J Cardiol"},{"key":"10239_CR14","doi-asserted-by":"crossref","unstructured":"Fernandez AI, Yotti R, Gonzalez-Mansilla A, Mombiela T, Gutierrez-Ibanes E, Perez Del Villar C, Navas-Tejedor P, Chazo C, Martinez-Legazpi P, Fernandez-Aviles F et al (2019) The biological bases of group 2 pulmonary hypertension. Int J Mol Sci\u00a020(23)","DOI":"10.3390\/ijms20235884"},{"issue":"6","key":"10239_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/HYPERTENSIONAHA.119.14330","volume":"75","author":"MS Al-Omary","year":"2020","unstructured":"Al-Omary MS, Sugito S, Boyle AJ, Sverdlov AL, Collins NJ (2020) Pulmonary hypertension due to left heart disease: diagnosis, pathophysiology, and therapy. Hypertension 75(6):1397\u20131408","journal-title":"Hypertension"},{"key":"10239_CR16","doi-asserted-by":"crossref","unstructured":"Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, Coghlan G, Chazova I, De Marco T (2019) Pulmonary hypertension due to left heart disease. Eur Respir J\u00a053(1)","DOI":"10.1183\/13993003.01897-2018"},{"issue":"2","key":"10239_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/HCO.0000000000000834","volume":"36","author":"A Duran","year":"2021","unstructured":"Duran A, Mandras S (2021) Pulmonary hypertension in heart failure. Curr Opin Cardiol 36(2):205\u2013210","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"10239_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D\u2019Alto M, Olsson KM, Ulrich S et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68(4):368\u2013378","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10239_CR19","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.hlc.2018.04.299","volume":"28","author":"AM Selim","year":"2019","unstructured":"Selim AM, Wadhwani L, Burdorf A, Raichlin E, Lowes B, Zolty R (2019) Left ventricular assist devices in pulmonary hypertension group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 28(6):946\u2013952","journal-title":"Heart Lung Circ"},{"issue":"3","key":"10239_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.15420\/cfr.2019.15.2","volume":"5","author":"M Arrigo","year":"2019","unstructured":"Arrigo M, Huber LC, Winnik S, Mikulicic F, Guidetti F, Frank M, Flammer AJ, Ruschitzka F (2019) Right ventricular failure: pathophysiology, diagnosis and treatment. Card Fail Rev 5(3):140\u2013146","journal-title":"Card Fail Rev"},{"issue":"13","key":"10239_CR21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.107.653584","volume":"117","author":"F Haddad","year":"2008","unstructured":"Haddad F, Doyle R, Murphy DJ, Hunt SA (2008) Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117(13):1717\u20131731","journal-title":"Circulation"},{"issue":"11","key":"10239_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.107.653576","volume":"117","author":"F Haddad","year":"2008","unstructured":"Haddad F, Hunt SA, Rosenthal DN, Murphy DJ (2008) Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117(11):1436\u20131448","journal-title":"Circulation"},{"issue":"134","key":"10239_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1183\/09059180.00007414","volume":"23","author":"R Naeije","year":"2014","unstructured":"Naeije R, Manes A (2014) The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 23(134):476\u2013487","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10239_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","volume":"115","author":"JJ Ryan","year":"2014","unstructured":"Ryan JJ, Archer SL (2014) The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 115(1):176\u2013188","journal-title":"Circ Res"},{"key":"10239_CR25","doi-asserted-by":"crossref","unstructured":"Naeije R, Richter MJ, Rubin LJ (2021) The physiologic basis of pulmonary arterial hypertension. Eur Respir J","DOI":"10.1183\/13993003.02334-2021"},{"key":"10239_CR26","doi-asserted-by":"crossref","unstructured":"Querejeta Roca G, Campbell P, Claggett B, Solomon SD, Shah AM (2015) Right atrial function in pulmonary arterial hypertension. Circ Cardiovasc Imaging\u00a08(11):e003521; discussion e003521","DOI":"10.1161\/CIRCIMAGING.115.003521"},{"key":"10239_CR27","doi-asserted-by":"crossref","unstructured":"Marra AM, Sherman AE, Salzano A, Guazzi M, Saggar R, Squire IB, Cittadini A, Channick RN, Bossone E (2022) Right side of the heart pulmonary circulation unit involvement in left-sided heart failure: Diagnostic, prognostic, and therapeutic implications. Chest 161(2):535\u2013551","DOI":"10.1016\/j.chest.2021.09.023"},{"issue":"2","key":"10239_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccl.2020.01.005","volume":"38","author":"FD Pagani","year":"2020","unstructured":"Pagani FD (2020) Right heart failure after left ventricular assist device placement: medical and surgical management considerations. Cardiol Clin 38(2):227\u2013238","journal-title":"Cardiol Clin"},{"issue":"8","key":"10239_CR29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2010.08.648","volume":"57","author":"M Hardziyenka","year":"2011","unstructured":"Hardziyenka M, Campian ME, Reesink HJ, Surie S, Bouma BJ, Groenink M, Klemens CA, Beekman L, Remme CA, Bresser P et al (2011) Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass: evidence for atrophic remodeling. J Am Coll Cardiol 57(8):921\u2013928","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10239_CR30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.echo.2019.05.008","volume":"32","author":"K Kishiki","year":"2019","unstructured":"Kishiki K, Singh A, Narang A, Gomberg-Maitland M, Goyal N, Maffessanti F, Besser SA, Mor-Avi V, Lang RM, Addetia K (2019) Impact of severe pulmonary arterial hypertension on the left heart and prognostic implications. J Am Soc Echocardiogr 32(9):1128\u20131137","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"10239_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/2045893217716107","volume":"7","author":"A Hirashiki","year":"2017","unstructured":"Hirashiki A, Adachi S, Nakano Y, Kamimura Y, Ogo T, Nakanishi N, Morisaki T, Morisaki H, Shimizu A, Toba K et al (2017) Left main coronary artery compression by a dilated main pulmonary artery and left coronary sinus of Valsalva aneurysm in a patient with heritable pulmonary arterial hypertension and FLNA mutation. Pulm Circ 7(3):734\u2013740","journal-title":"Pulm Circ"},{"issue":"5","key":"10239_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/eurheartj\/ehv548","volume":"37","author":"AM Katz","year":"2016","unstructured":"Katz AM, Rolett EL (2016) Heart failure: when form fails to follow function. Eur Heart J 37(5):449\u2013454","journal-title":"Eur Heart J"},{"issue":"11","key":"10239_CR33","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ejhf.645","volume":"18","author":"F Triposkiadis","year":"2016","unstructured":"Triposkiadis F, Pieske B, Butler J, Parissis J, Giamouzis G, Skoularigis J, Brutsaert D, Boudoulas H (2016) Global left atrial failure in heart failure. Eur J Heart Fail 18(11):1307\u20131320","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10239_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ejhf.1643","volume":"22","author":"MS Khan","year":"2020","unstructured":"Khan MS, Memon MM, Murad MH, Vaduganathan M, Greene SJ, Hall M, Triposkiadis F, Lam CSP, Shah AM, Butler J et al (2020) Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 22(3):472\u2013485","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10239_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/1089253218799345","volume":"23","author":"JM Del Rio","year":"2019","unstructured":"Del Rio JM, Grecu L, Nicoara A (2019) Right ventricular function in left heart disease. Semin Cardiothorac Vasc Anesth 23(1):88\u2013107","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10239_CR36","doi-asserted-by":"crossref","unstructured":"Wanner PM, Filipovic M (2020) The right ventricle-you may forget it, but it will not forget you. J Clin Med 9(2)","DOI":"10.3390\/jcm9020432"},{"key":"10239_CR37","unstructured":"Janicki JS (1990) Influence of the pericardium and ventricular interdependence on left ventricular diastolic and systolic function in patients with heart failure. Circulation\u00a081(2 Suppl):III15\u201320"},{"issue":"7","key":"10239_CR38","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","volume":"7","author":"BA Borlaug","year":"2019","unstructured":"Borlaug BA, Reddy YNV (2019) The role of the pericardium in heart failure: implications for pathophysiology and treatment. JACC Heart Fail 7(7):574\u2013585","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10239_CR39","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0022-5223(12)70150-2","volume":"107","author":"D Hoffman","year":"1994","unstructured":"Hoffman D, Sisto D, Frater RW, Nikolic SD (1994) Left-to-right ventricular interaction with a noncontracting right ventricle. J Thorac Cardiovasc Surg 107(6):1496\u20131502","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10239_CR40","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.21037\/cdt-20-479","volume":"10","author":"RJ Bernardo","year":"2020","unstructured":"Bernardo RJ, Haddad F, Couture EJ, Hansmann G, de Jesus Perez VA, Denault AY, de Man FS, Amsallem M (2020) Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction. Cardiovasc Diagn Ther 10(5):1580\u20131603","journal-title":"Cardiovasc Diagn Ther"},{"key":"10239_CR41","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fphys.2018.00520","volume":"9","author":"KL Sack","year":"2018","unstructured":"Sack KL, Dabiri Y, Franz T, Solomon SD, Burkhoff D, Guccione JM (2018) Investigating the role of interventricular interdependence in development of right heart dysfunction during LVAD support: a patient-specific methods-based approach. Front Physiol 9:520","journal-title":"Front Physiol"},{"key":"10239_CR42","doi-asserted-by":"crossref","unstructured":"Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829\u2013837, 837a\u2013837d","DOI":"10.1093\/eurheartj\/ehr304"},{"issue":"3","key":"10239_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10557-020-06959-1","volume":"34","author":"MEJ Preedy","year":"2020","unstructured":"Preedy MEJ (2020) Cardiac cyclic nucleotide phosphodiesterases: roles and therapeutic potential in heart failure. Cardiovasc Drugs Ther 34(3):401\u2013417","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"10239_CR44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1161\/CIRCRESAHA.117.303776","volume":"120","author":"JR Kraehling","year":"2017","unstructured":"Kraehling JR, Sessa WC (2017) Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease. Circ Res 120(7):1174\u20131182","journal-title":"Circ Res"},{"issue":"5","key":"10239_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","volume":"15","author":"C Farah","year":"2018","unstructured":"Farah C, Michel LYM, Balligand JL (2018) Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol 15(5):292\u2013316","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"10239_CR46","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1161\/01.CIR.0000094403.78467.C3","volume":"108","author":"T Munzel","year":"2003","unstructured":"Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U (2003) Physiology and pathophysiology of vascular signaling controlled by guanosine 3\u2019,5\u2019-cyclic monophosphate-dependent protein kinase [corrected]. Circulation 108(18):2172\u20132183","journal-title":"Circulation"},{"issue":"10","key":"10239_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/01.RES.0000100390.68771.CC","volume":"93","author":"R Feil","year":"2003","unstructured":"Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F (2003) Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 93(10):907\u2013916","journal-title":"Circ Res"},{"issue":"8","key":"10239_CR48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/01.RES.0000246118.98832.04","volume":"99","author":"R Fischmeister","year":"2006","unstructured":"Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99(8):816\u2013828","journal-title":"Circ Res"},{"issue":"2","key":"10239_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/er.2013-1053","volume":"35","author":"MF Azevedo","year":"2014","unstructured":"Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA (2014) Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 35(2):195\u2013233","journal-title":"Endocr Rev"},{"issue":"2","key":"10239_CR50","first-page":"14","volume":"2017","author":"AH Chester","year":"2017","unstructured":"Chester AH, Yacoub MH, Moncada S (2017) Nitric oxide and pulmonary arterial hypertension. Glob Cardiol Sci Pract 2017(2):14","journal-title":"Glob Cardiol Sci Pract"},{"issue":"8S","key":"10239_CR51","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.amjcard.2017.06.012","volume":"120","author":"JR Klinger","year":"2017","unstructured":"Klinger JR, Kadowitz PJ (2017) The nitric oxide pathway in pulmonary vascular disease. Am J Cardiol 120(8S):S71\u2013S79","journal-title":"Am J Cardiol"},{"issue":"4","key":"10239_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A Giaid","year":"1995","unstructured":"Giaid A, Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333(4):214\u2013221","journal-title":"N Engl J Med"},{"issue":"3","key":"10239_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8","volume":"185","author":"NA Mason","year":"1998","unstructured":"Mason NA, Springall DR, Burke M, Pollock J, Mikhail G, Yacoub MH, Polak JM (1998) High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 185(3):313\u2013318","journal-title":"J Pathol"},{"issue":"20","key":"10239_CR54","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123(20):2263\u20132273","journal-title":"Circulation"},{"issue":"2","key":"10239_CR55","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1152\/physrev.00022.2015","volume":"96","author":"M Kuhn","year":"2016","unstructured":"Kuhn M (2016) Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev 96(2):751\u2013804","journal-title":"Physiol Rev"},{"issue":"5","key":"10239_CR56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/FJC.0000000000000749","volume":"75","author":"RM Blanton","year":"2020","unstructured":"Blanton RM (2020) cGMP signaling and modulation in heart failure. J Cardiovasc Pharmacol 75(5):385\u2013398","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"10239_CR57","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/ejhf.1837","volume":"22","author":"F Triposkiadis","year":"2020","unstructured":"Triposkiadis F, Xanthopoulos A, Butler J (2020) From Paradigm to Paragon further evidence supporting continuous heart failure spectrum. Eur J Heart Fail 22(9):1536\u20131539","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10239_CR58","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/CIRCHEARTFAILURE.113.000575","volume":"6","author":"Q Kong","year":"2013","unstructured":"Kong Q, Blanton RM (2013) Protein kinase G I and heart failure: shifting focus from vascular unloading to direct myocardial antiremodeling effects. Circ Heart Fail 6(6):1268\u20131283","journal-title":"Circ Heart Fail"},{"key":"10239_CR59","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.freeradbiomed.2014.05.016","volume":"73","author":"BE Sansbury","year":"2014","unstructured":"Sansbury BE, Hill BG (2014) Regulation of obesity and insulin resistance by nitric oxide. Free Radic Biol Med 73:383\u2013399","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10239_CR60","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1006\/jmcc.2000.1334","volume":"33","author":"N Paolocci","year":"2001","unstructured":"Paolocci N, Biondi R, Bettini M, Lee CI, Berlowitz CO, Rossi R, Xia Y, Ambrosio G, L\u2019Abbate A, Kass DA et al (2001) Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart. J Mol Cell Cardiol 33(4):671\u2013679","journal-title":"J Mol Cell Cardiol"},{"issue":"22","key":"10239_CR61","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.2174\/13816128113196660748","volume":"20","author":"S Karbach","year":"2014","unstructured":"Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A (2014) eNOS uncoupling in cardiovascular diseases\u2013the role of oxidative stress and inflammation. Curr Pharm Des 20(22):3579\u20133594","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10239_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/hh0102.102330","volume":"90","author":"LJ Ignarro","year":"2002","unstructured":"Ignarro LJ, Napoli C, Loscalzo J (2002) Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90(1):21\u201328","journal-title":"Circ Res"},{"issue":"36","key":"10239_CR63","doi-asserted-by":"publisher","first-page":"9442","DOI":"10.1002\/anie.201302588","volume":"52","author":"M Follmann","year":"2013","unstructured":"Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, Schafer M, Schirok H, Stasch JP, Stoll F et al (2013) The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 52(36):9442\u20139462","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"10239_CR64","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","volume":"165","author":"T Keravis","year":"2012","unstructured":"Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165(5):1288\u20131305","journal-title":"Br J Pharmacol"},{"issue":"15","key":"10239_CR65","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","volume":"104","author":"DC Hutchings","year":"2018","unstructured":"Hutchings DC, Anderson SG, Caldwell JL, Trafford AW (2018) Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart 104(15):1244\u20131250","journal-title":"Heart"},{"key":"10239_CR66","doi-asserted-by":"crossref","unstructured":"Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, Roessig L, Stasch JP (2021) Soluble GC stimulators and activators: past, present and future. Br J Pharmacol","DOI":"10.1111\/bph.15698"},{"issue":"6","key":"10239_CR67","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/10742484211042706","volume":"26","author":"DJ Cordwin","year":"2021","unstructured":"Cordwin DJ, Berei TJ, Pogue KT (2021) The role of sGC stimulators and activators in heart failure with reduced ejection fraction. J Cardiovasc Pharmacol Ther 26(6):593\u2013600","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10239_CR68","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/164_2018_197","volume":"264","author":"P Sandner","year":"2021","unstructured":"Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP (2021) Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol 264:355\u2013394","journal-title":"Handb Exp Pharmacol"},{"issue":"25","key":"10239_CR69","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun PM (2021) Pulmonary arterial hypertension. N Engl J Med 385(25):2361\u20132376","journal-title":"N Engl J Med"},{"issue":"1","key":"10239_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12170-020-00663-3","volume":"15","author":"JD Mayeux","year":"2021","unstructured":"Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, Beck E, Hatton ND, Ryan JJ (2021) Management of pulmonary arterial hypertension. Curr Cardiovasc Risk Rep 15(1):2","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"1","key":"10239_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.15420\/ecr.2017:22:2","volume":"13","author":"H Watanabe","year":"2018","unstructured":"Watanabe H (2018) Treatment selection in pulmonary arterial hypertension: phosphodiesterase type 5 inhibitors versus soluble guanylate cyclase stimulator. Eur Cardiol 13(1):35\u201337","journal-title":"Eur Cardiol"},{"issue":"14","key":"10239_CR72","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","volume":"116","author":"GD Lewis","year":"2007","unstructured":"Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD et al (2007) Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116(14):1555\u20131562","journal-title":"Circulation"},{"issue":"1","key":"10239_CR73","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12872-020-01671-2","volume":"20","author":"E Belyavskiy","year":"2020","unstructured":"Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F (2020) Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovasc Disord 20(1):408","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"10239_CR74","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309(12):1268\u20131277","journal-title":"JAMA"},{"issue":"15","key":"10239_CR75","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","volume":"39","author":"J Bermejo","year":"2018","unstructured":"Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, Segovia-Cubero J, Escribano-Subias P, San Roman JA, Borras X, Alonso-Gomez A et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 39(15):1255\u20131264","journal-title":"Eur Heart J"},{"issue":"2","key":"10239_CR76","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MAT.0000000000000626","volume":"64","author":"AK Ravichandran","year":"2018","unstructured":"Ravichandran AK, LaRue SJ, Novak E, Joseph SA, Schilling JD (2018) Sildenafil in left ventricular assist device is safe and well-tolerated. ASAIO J 64(2):280\u2013281","journal-title":"ASAIO J"},{"key":"10239_CR77","doi-asserted-by":"crossref","unstructured":"Gulati G, Grandin EW, Kennedy K, Cabezas F, DeNofrio DD, Kociol R, Rame JE, Pagani FD, Kirklin JK, Kormos RL et al (2019)\u00a0Preimplant phosphodiesterase-5 inhibitor use is associated with higher rates of severe early right heart failure after left ventricular assist device implantation. Circ Heart Fail 12(6):e005537","DOI":"10.1161\/CIRCHEARTFAILURE.118.005537"},{"issue":"5","key":"10239_CR78","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"D Bonderman","year":"2013","unstructured":"Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128(5):502\u2013511","journal-title":"Circulation"},{"issue":"21","key":"10239_CR79","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E et al (2015) Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the socrates-reduced randomized trial. JAMA 314(21):2251\u20132262","journal-title":"JAMA"},{"issue":"20","key":"10239_CR80","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"key":"10239_CR81","doi-asserted-by":"crossref","unstructured":"Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O'Connor CM, Roessig L, Patel MJ et al (2021) Blood pressure and safety events with vericiguat in the victoria trial. J Am Heart Assoc 10(22):e021094","DOI":"10.1161\/JAHA.121.021094"},{"issue":"20","key":"10239_CR82","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","volume":"105","author":"E Michelakis","year":"2002","unstructured":"Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105(20):2398\u20132403","journal-title":"Circulation"},{"issue":"2","key":"10239_CR83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cardfail.2020.11.007","volume":"27","author":"L Monzo","year":"2021","unstructured":"Monzo L, Reichenbach A, Al-Hiti H, Borlaug BA, Havlenova T, Solar N, Tupy M, Ters J, Kautzner J, Melenovsky V (2021) Acute unloading effects of sildenafil enhance right ventricular-pulmonary artery coupling in heart failure. J Card Fail 27(2):224\u2013232","journal-title":"J Card Fail"},{"issue":"8","key":"10239_CR84","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1073\/pnas.73.8.2559","volume":"73","author":"TM Lincoln","year":"1976","unstructured":"Lincoln TM, Hall CL, Park CR, Corbin JD (1976) Guanosine 3\u2019:5\u2019-cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci U S A 73(8):2559\u20132563","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10239_CR85","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","volume":"334","author":"JD Corbin","year":"2005","unstructured":"Corbin JD, Beasley A, Blount MA, Francis SH (2005) High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334(3):930\u2013938","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10239_CR86","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","volume":"172","author":"J Wharton","year":"2005","unstructured":"Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172(1):105\u2013113","journal-title":"Am J Respir Crit Care Med"},{"issue":"38","key":"10239_CR87","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","volume":"36","author":"ES Hoendermis","year":"2015","unstructured":"Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA (2015) Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36(38):2565\u20132573","journal-title":"Eur Heart J"},{"issue":"6","key":"10239_CR88","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamacardio.2018.0318","volume":"3","author":"YNV Reddy","year":"2018","unstructured":"Reddy YNV, El-Sabbagh A, Nishimura RA (2018) Comparing pulmonary arterial wedge pressure and left ventricular end diastolic pressure for assessment of left-sided filling pressures. JAMA Cardiol 3(6):453\u2013454","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10239_CR89","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.chest.2018.08.1033","volume":"154","author":"AR Hemnes","year":"2018","unstructured":"Hemnes AR, Opotowsky AR, Assad TR, Xu M, Doss LN, Farber-Eger E, Wells QS, Brittain EL (2018) Features associated with discordance between pulmonary arterial wedge pressure and left ventricular end diastolic pressure in clinical practice: implications for pulmonary hypertension classification. Chest 154(5):1099\u20131107","journal-title":"Chest"},{"issue":"5","key":"10239_CR90","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.healun.2013.01.988","volume":"32","author":"D Schranz","year":"2013","unstructured":"Schranz D, Rupp S, Muller M, Schmidt D, Bauer A, Valeske K, Michel-Behnke I, Jux C, Apitz C, Thul J et al (2013) Pulmonary artery banding in infants and young children with left ventricular dilated cardiomyopathy: a novel therapeutic strategy before heart transplantation. J Heart Lung Transplant 32(5):475\u2013481","journal-title":"J Heart Lung Transplant"},{"issue":"13","key":"10239_CR91","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1161\/CIRCULATIONAHA.117.029360","volume":"137","author":"D Schranz","year":"2018","unstructured":"Schranz D, Akintuerk H, Bailey L (2018) Pulmonary artery banding for functional regeneration of end-stage dilated cardiomyopathy in young children: World Network Report. Circulation 137(13):1410\u20131412","journal-title":"Circulation"},{"key":"10239_CR92","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fped.2020.00347","volume":"8","author":"A Di Candia","year":"2020","unstructured":"Di Candia A, Castaldi B, Bordin G, Cerutti A, Reffo E, Biffanti R, Di Salvo G, Vida VL, Padalino MA (2020) Pulmonary artery banding for ventricular rehabilitation in infants with dilated cardiomyopathy: early results in a single-center experience. Front Pediatr 8:347","journal-title":"Front Pediatr"},{"issue":"2","key":"10239_CR93","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21037\/tp.2019.04.09","volume":"8","author":"D Schranz","year":"2019","unstructured":"Schranz D, Recla S, Malcic I, Kerst G, Mini N, Akintuerk H (2019) Pulmonary artery banding in dilative cardiomyopathy of young children: review and protocol based on the current knowledge. Transl Pediatr 8(2):151\u2013160","journal-title":"Transl Pediatr"},{"key":"10239_CR94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1749-8090-7-60","volume":"7","author":"S Neragi-Miandoab","year":"2012","unstructured":"Neragi-Miandoab S, Goldstein D, Bello R, Michler R, D\u2019Alessandro D (2012) Right ventricular dysfunction following continuous flow left ventricular assist device placement in 51 patients: predicators and outcomes. J Cardiothorac Surg 7:60","journal-title":"J Cardiothorac Surg"},{"issue":"3","key":"10239_CR95","doi-asserted-by":"publisher","first-page":"407","DOI":"10.21470\/1678-9741-2020-0058","volume":"35","author":"R Magoon","year":"2020","unstructured":"Magoon R, Jose J, Kohli JK, Kashav R (2020) Altered RV mechanics post-LVAD insertion: a physiological perspective! Braz J Cardiovasc Surg 35(3):407\u2013408","journal-title":"Braz J Cardiovasc Surg"},{"issue":"1","key":"10239_CR96","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5114\/aoms.2013.33616","volume":"11","author":"MI El-Sayed","year":"2015","unstructured":"El-Sayed MI, Amin HA (2015) Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit. Arch Med Sci 11(1):190\u2013198","journal-title":"Arch Med Sci"},{"issue":"1","key":"10239_CR97","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1074248420940897","volume":"26","author":"T Naesheim","year":"2021","unstructured":"Naesheim T, How OJ, Myrmel T (2021) Hemodynamic effects of a soluble guanylate cyclase stimulator, riociguat, and an activator, cinaciguat, during NO-modulation in healthy pigs. J Cardiovasc Pharmacol Ther 26(1):75\u201387","journal-title":"J Cardiovasc Pharmacol Ther"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10239-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-022-10239-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10239-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T07:18:14Z","timestamp":1665127094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-022-10239-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10239"],"URL":"https:\/\/doi.org\/10.1007\/s10741-022-10239-5","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"5 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}